Scisparc aims to change tourette syndrome treatments; will start a phase iib trial with its innovative pharma-grade thc-based medication

Scisparc to conduct trial at yale university in the usa, tel aviv sourasky medical center in israel and the hannover medical school in germany

SPRC Ratings Summary

SPRC Quant Ranking